Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Washington University

www.wustl.edu

Latest From Washington University

Tech Transfer Roundup: Roivant Taps Research Labs For New Gene Therapies

In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.

Business Strategies Commercial

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

Deals Intellectual Property

Tech Transfer Roundup: ProQR Partners With Foundation Fighting Blindness On Rare Vision-Loss Disorder

Galderma unveils seven-year partnership with Mount Sinai and Northwestern in atopic dermatitis. Beacon/Takeda and Zealand/UniQuest tie-ups both address gastrointestinal diseases.

Deals Business Strategies

A Different Approach To Corporate Venture: An Interview With AbbVie Ventures' Scott Brun

AbbVie Ventures is young, but the group was set up with specific goals: to invest specifically in tune with AbbVie's therapeutic focus areas and not to focus purely on return on investment.

Business Strategies Financing
See All
UsernamePublicRestriction

Register